Vivalytic | Viral Respiratory Infection Array
Detecting SARS-CoV-2 (COVID-19)
The new Viral Respiratory Infection Array (VRI) will be conducted on Vivalytic, a point of care platform brought to the market by Randox Laboratories and Bosch. The Vivalytic system is a fully-automated, cartridge-based platform capable of both Hi-Plex and Lo-Plex testing. The VRI test can identify SARS-CoV-2 (COVID-19) and differentiate it from nine other respiratory infections with similar symptoms, including influenza and all known coronaviruses.
|Influenza A||Coronavirus OC43/HKUI||Parainfluenza virus 3|
|Influenza B||Enterovirus A/B/C||Parainfluenza virus 4|
|Adenovirus A/B/C/D/E||Metapneumovirus||Respiratory syncytial virus A/B|
|Bocavirus 1/2/3||Parainfluenza virus 1||Rhinovirus A/B/C|
|Coronavirus 229E/NL63||Parainfluenza virus 2||SARS-CoV-2 (COVID-19)|
Vivalytic cartridges are compact, technologically advanced Molecular Diagnostic tests utilising micro-fluidics to enable simple and accurate diagnostic testing. Randox patented Biochip Array Technology powers Vivalytic, enabling end-point qualitative PCR and providing multiple test results from each sample.